328 related articles for article (PubMed ID: 19800278)
1. Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.
Lee CH; Su LH; Lin WC; Tang YF; Liu JW
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e183-6. PubMed ID: 19800278
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
[TBL] [Abstract][Full Text] [Related]
3. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
4. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
[TBL] [Abstract][Full Text] [Related]
5. CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.
Celik AD; Yulugkural Z; Kuloglu F; Eroglu C; Torol S; Vahaboğlu H; Akata F
J Microbiol Immunol Infect; 2010 Apr; 43(2):163-7. PubMed ID: 20457435
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
7. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
[TBL] [Abstract][Full Text] [Related]
11. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
[TBL] [Abstract][Full Text] [Related]
12. Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008.
Qi C; Pilla V; Yu JH; Reed K
Diagn Microbiol Infect Dis; 2010 May; 67(1):87-91. PubMed ID: 20227224
[TBL] [Abstract][Full Text] [Related]
13. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
[TBL] [Abstract][Full Text] [Related]
14. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
[TBL] [Abstract][Full Text] [Related]
15. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia.
Kader AA; Angamuthu K
Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682
[TBL] [Abstract][Full Text] [Related]
16. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
17. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
[No Abstract] [Full Text] [Related]
18. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010.
Hoban DJ; Nicolle LE; Hawser S; Bouchillon S; Badal R
Diagn Microbiol Infect Dis; 2011 Aug; 70(4):507-11. PubMed ID: 21767706
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
